-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In order to accelerate the development and commercialization of innovative drugs, cooperation between pharmaceutical companies is becoming more and more frequent
.
Among them, it is worth mentioning that the more leading companies, the more they like to join forces
.
For example, recently, many large multinational pharmaceutical companies have set off a wave of cooperation
.
On March 15, Sanofi and Blackstone Life Sciences announced a strategic collaboration
.
Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients
.
Sanofi will continue to fully manage the clinical program
.
If successful, Blackstone Life Sciences will be eligible to receive royalties on future product sales
.
The pivotal study is expected to begin in the second half of 2022
.
It is worth mentioning that Sanofi just announced a research cooperation and exclusive technology licensing agreement with Tianyan Pharmaceutical (ADAG.
US) not long ago.
Tianyan Pharmaceutical will lead early research and development activities, using its unique technology.
Safety Antibody SAFEbody technology develops precise masked safety antibodies of the new generation of monoclonal and bispecific antibodies provided by Sanofi, and Sanofi will be responsible for further research and development, product development and commercialization activities in the future
.
On March 8, Voyager announced that it has reached a licensing and R&D agreement with Novartis.
According to the cooperation agreement, Novartis has the right to evaluate the innovative capsids discovered by the Voyager technology platform, and has full access to the development rights of specific capsids for the development of targeted CNS targets.
Point of AAV gene therapy
.
Voyager will receive an up-front payment of $54 million and is eligible to receive milestone payments totaling up to $1.
7 billion
.
Data show that AAV vector is one of the important vectors for delivering gene therapy and other gene medicine products
.
Voyager's AAV capsid discovery platform has identified a series of AAV capsids with unique characteristics that provide better ability to cross the blood-brain barrier and improve transfection in the brain and spinal cord
.
In addition to the above-mentioned pharmaceutical companies, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical and other companies have also announced new cooperation announcements this year
.
The analysis believes that this is mainly due to the influence of changes in the pharmaceutical industry, and pharmaceutical companies have successively adjusted their strategies and increased R&D pipelines in order to accelerate innovation
.
Of course, there are new cooperations, and naturally there are also companies that terminate cooperation
.
On March 16, the combination therapy of Merck's blockbuster Keytruda and AstraZeneca's Lynparza failed to outperform the current clinically commonly used anti-androgen therapy in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC).
The company immediately announced that it would discontinue the development of the Keytruda-Lynparza combination therapy
.
In this regard, analysts said that a large number of domestic and foreign pharmaceutical companies have recently announced that they will cooperate with other companies or terminate cooperation
.
In fact, this has become the norm in the industry.
Out of optimism about the market development in some pharmaceutical fields, many pharmaceutical companies choose to cooperate to accelerate product development
.
In the case of failure in research and development, etc.
, it is announced that the cooperation will be terminated
.
In the future, under the background of accelerated reshuffle in the pharmaceutical industry and accelerated innovation and transformation of pharmaceutical companies, the industry expects that domestic and foreign pharmaceutical companies will be more and more frequent in order to better promote R&D innovation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, it is worth mentioning that the more leading companies, the more they like to join forces
.
For example, recently, many large multinational pharmaceutical companies have set off a wave of cooperation
.
On March 15, Sanofi and Blackstone Life Sciences announced a strategic collaboration
.
Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients
.
Sanofi will continue to fully manage the clinical program
.
If successful, Blackstone Life Sciences will be eligible to receive royalties on future product sales
.
The pivotal study is expected to begin in the second half of 2022
.
It is worth mentioning that Sanofi just announced a research cooperation and exclusive technology licensing agreement with Tianyan Pharmaceutical (ADAG.
US) not long ago.
Tianyan Pharmaceutical will lead early research and development activities, using its unique technology.
Safety Antibody SAFEbody technology develops precise masked safety antibodies of the new generation of monoclonal and bispecific antibodies provided by Sanofi, and Sanofi will be responsible for further research and development, product development and commercialization activities in the future
.
On March 8, Voyager announced that it has reached a licensing and R&D agreement with Novartis.
According to the cooperation agreement, Novartis has the right to evaluate the innovative capsids discovered by the Voyager technology platform, and has full access to the development rights of specific capsids for the development of targeted CNS targets.
Point of AAV gene therapy
.
Voyager will receive an up-front payment of $54 million and is eligible to receive milestone payments totaling up to $1.
7 billion
.
Data show that AAV vector is one of the important vectors for delivering gene therapy and other gene medicine products
.
Voyager's AAV capsid discovery platform has identified a series of AAV capsids with unique characteristics that provide better ability to cross the blood-brain barrier and improve transfection in the brain and spinal cord
.
In addition to the above-mentioned pharmaceutical companies, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical and other companies have also announced new cooperation announcements this year
.
The analysis believes that this is mainly due to the influence of changes in the pharmaceutical industry, and pharmaceutical companies have successively adjusted their strategies and increased R&D pipelines in order to accelerate innovation
.
Of course, there are new cooperations, and naturally there are also companies that terminate cooperation
.
On March 16, the combination therapy of Merck's blockbuster Keytruda and AstraZeneca's Lynparza failed to outperform the current clinically commonly used anti-androgen therapy in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC).
The company immediately announced that it would discontinue the development of the Keytruda-Lynparza combination therapy
.
In this regard, analysts said that a large number of domestic and foreign pharmaceutical companies have recently announced that they will cooperate with other companies or terminate cooperation
.
In fact, this has become the norm in the industry.
Out of optimism about the market development in some pharmaceutical fields, many pharmaceutical companies choose to cooperate to accelerate product development
.
In the case of failure in research and development, etc.
, it is announced that the cooperation will be terminated
.
In the future, under the background of accelerated reshuffle in the pharmaceutical industry and accelerated innovation and transformation of pharmaceutical companies, the industry expects that domestic and foreign pharmaceutical companies will be more and more frequent in order to better promote R&D innovation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
